Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  ImmunoPrecise Antibodies Ltd.    IPA   CA45257F2008

IMMUNOPRECISE ANTIBODIES LTD.

(IPA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

ImmunoPrecise Antibodies : and Genmab Enter into a Technology Partnership Targeting Infectious Disease

11/20/2020 | 08:49am EST

VICTORIA - IMMUNOPRECISE ANTIBODIES LTD. (the 'Company' or 'IPA') (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a research agreement with Genmab A/S (Nasdaq: GMAB), an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

IPA will generate novel bispecific antibody combinations using Genmab's proprietary DuoBody platform and IPA's proprietary antibodies in the field of infectious disease. The development of IPA's proprietary antibodies into DuoBody constructs enables additional, novel formulations as the Company investigates a series of combinations in parallel.

'Partnering with Genmab aligns with IPA's mission to develop safe and effective therapies for patients, in this case, specifically pertaining to the growing demand in infectious disease,' said Dr. Jennifer Bath, Chief Executive Officer of ImmunoPrecise Antibodies. 'This agreement further complements our strategy to ensure that the full potential of our infectious disease programs is realized, which includes establishing productive partnerships to increase opportunities for ideal formulations with the highest safety and efficacy profiles.'

The DuoBody technology is a proprietary platform of Genmab applied in the discovery and development of bispecific antibodies across several therapeutic areas including cancer, hemophilia, autoimmune, infectious, and central nervous system diseases. DuoBody technology has been successfully used in many Genmab internal or partnered investigational clinical therapies.

As a part of the partnership, Genmab and IPA will negotiate in good faith an agreement for the commercial use of resulting DuoBody products.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company's experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise's full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development.

Contact:

Frederick Chabot

Tel: 1-438-863-7071

Email: frederick@contactfinancial.com

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute 'forward-looking statements' within the meaning of applicable Canadian securities laws. The Company uses words such as 'may', 'would', 'could', 'will', 'likely', 'expect', 'believe', 'intend', 'should' and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the previous quarter ended July 31, 2020 which can be accessed at www.sedar.com. The 'forward-looking statements' contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
GENMAB A/S 0.94% 2687 Delayed Quote.9.09%
IMMUNOPRECISE ANTIBODIES LTD. -2.45% 18.35 Delayed Quote.-5.61%
All news about IMMUNOPRECISE ANTIBODIES LTD.
01/06IMMUNOPRECISE ANTIBODIES : Announces Grant of Stock Options
BU
01/06IMMUNOPRECISE ANTIBODIES : to Participate in January Conferences
BU
2020Update - Dual Listed ImmunoPrecise Down 10% on TSX As Partners on Launch of S..
MT
2020IMMUNOPRECISE ANTIBODIES : Dual Listed ImmunoPrecise Partners on Launch of SARS-..
MT
2020IMMUNOPRECISE BRIEF : Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Prog..
MT
2020IMMUNOPRECISE ANTIBODIES : Partners on Launch of SARS-CoV-2 Nanomedicine Therapy..
BU
2020ImmunoPrecise Antibodies to Begin Trading on the NASDAQ
MT
2020IMMUNOPRECISE ANTIBODIES : to Begin Trading on Nasdaq Stock Exchange
AQ
2020IMMUNOPRECISE ANTIBODIES : Reports 50% Jump in Revenue to $4.75 Million For Q2 2..
MT
2020IMMUNOPRECISE ANTIBODIES : Reports Financial Results and Recent Business Highlig..
AQ
More news
Financials
Sales 2021 20,4 M 16,0 M 16,0 M
Net income 2021 -2,59 M -2,03 M -2,03 M
Net Debt 2021 - - -
P/E ratio 2021 -131x
Yield 2021 -
Capitalization 313 M 245 M 245 M
Capi. / Sales 2021 15,3x
Capi. / Sales 2022 12,4x
Nbr of Employees -
Free-Float 92,4%
Chart IMMUNOPRECISE ANTIBODIES LTD.
Duration : Period :
ImmunoPrecise Antibodies Ltd. Technical Analysis Chart | IPA | CA45257F2008 | MarketScreener
Technical analysis trends IMMUNOPRECISE ANTIBODIES LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 20,00 CAD
Last Close Price 18,35 CAD
Spread / Highest target 8,99%
Spread / Average Target 8,99%
Spread / Lowest Target 8,99%
EPS Revisions
Managers and Directors
NameTitle
Jennifer Bath President, Chief Executive Officer & Director
James S. Kuo Chairman
Lisa Helbling Chief Financial Officer
Yasmina Noubia Abdiche Chief Scientific Officer
Gregory S. Smith Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOPRECISE ANTIBODIES LTD.-5.61%245
CSL LIMITED-5.62%93 853
SAMSUNG BIOLOGICS CO.,LTD.-2.66%48 243
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-2.71%35 533
ALEXION PHARMACEUTICALS, INC.0.26%34 293